• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours.

作者信息

Oosting Sjoukje F, van der Veldt Astrid A M, Fehrmann Rudolf S N, GeurtsvanKessel Corine H, van Binnendijk Rob S, Dingemans Anne-Marie C, Smit Egbert F, Hiltermann T Jeroen N, den Hartog Gerco, Jalving Mathilda, Westphal Tatjana T, Bhattacharya Arkajyoti, de Wilt Faye, Boerma Annemarie, van Zijl Lisanne, Rimmelzwaan Guus F, Kvistborg Pia, van Els Cecile A C M, Rots Nynke Y, van Baarle Debbie, Haanen John B A G, de Vries Elisabeth G E

机构信息

Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, Groningen, Netherlands.

Department of Medical Oncology, Erasmus Medical Centre, 3015 GD Rotterdam, Netherlands; Department of Radiology and Nuclear Medicine, Erasmus Medical Centre, 3015 GD Rotterdam, Netherlands.

出版信息

Lancet Oncol. 2022 Jul;23(7):833-835. doi: 10.1016/S1470-2045(22)00203-0. Epub 2022 Apr 25.

DOI:10.1016/S1470-2045(22)00203-0
PMID:
35483383
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9236566/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9211/9236566/6a3401584afe/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9211/9236566/6a3401584afe/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9211/9236566/6a3401584afe/gr1_lrg.jpg

相似文献

1
Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours.接受化疗、免疫治疗或两者联合治疗实体瘤的患者在接种第二剂和第三剂mRNA-1273疫苗后的免疫原性。
Lancet Oncol. 2022 Jul;23(7):833-835. doi: 10.1016/S1470-2045(22)00203-0. Epub 2022 Apr 25.
2
Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.针对 SARS-CoV-2 的三种不同疫苗加强免疫后的抗体反应动力学。
Front Immunol. 2022 Jan 19;13:811020. doi: 10.3389/fimmu.2022.811020. eCollection 2022.
3
Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccination.实体瘤患者接种 SARS-CoV-2 疫苗后可产生充分的免疫原性和较低的严重不良事件发生率。
Future Oncol. 2022 Jul;18(23):2537-2550. doi: 10.2217/fon-2022-0148. Epub 2022 Jun 9.
4
Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients - the Vienna Cohort.mRNA-1273 冠状病毒病 2019 疫苗接种在腹膜透析患者中的抗体反应和安全性 - 维也纳队列。
Front Immunol. 2021 Dec 2;12:780594. doi: 10.3389/fimmu.2021.780594. eCollection 2021.
5
COVID-19 and Cancer: Special Considerations for Patients Receiving Immunotherapy and Immunosuppressive Cancer Therapies.新型冠状病毒肺炎（COVID-19）与癌症：正在接受免疫疗法和免疫抑制性癌症治疗的患者的特殊考虑。
Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-13. doi: 10.1200/EDBK_359656.
6
Comparison of mRNA-1273 and BNT162b2 SARS-CoV-2 mRNA Vaccine Immunogenicity in Kidney Transplant Recipients.肾移植受者中mRNA-1273和BNT162b2新冠病毒mRNA疫苗免疫原性的比较
Transpl Int. 2022 Jan 4;35:10026. doi: 10.3389/ti.2021.10026. eCollection 2021.
7
Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis.重症肌无力患者中新型冠状病毒 mRNA-1273 疫苗的免疫反应和安全性。
Neurol Neuroimmunol Neuroinflamm. 2022 Jun 21;9(4). doi: 10.1212/NXI.0000000000200002. Print 2022 Jul.
8
Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection.个体感染 COVID-19 后再次感染，接种两剂 SARS-CoV-2 mRNA-1273 疫苗后的抗体反应。
Int J Infect Dis. 2022 Jun;119:18-20. doi: 10.1016/j.ijid.2022.03.017. Epub 2022 Mar 16.
9
Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida.佛罗里达州癌症患者对 SARS-CoV-2 mRNA-1273 疫苗的抗体反应评估。
JAMA Oncol. 2022 May 1;8(5):748-754. doi: 10.1001/jamaoncol.2022.0001.
10
Quantitative Analysis of SARS-CoV-2 Antibody Status between Patients with Cancer and Healthy Individuals with Extended Vaccination Dosing Intervals in Canada.加拿大延长接种间隔的癌症患者与健康个体的 SARS-CoV-2 抗体状态的定量分析。
Curr Oncol. 2021 Dec 24;29(1):68-76. doi: 10.3390/curroncol29010006.

引用本文的文献

1
mRNA-1273 vaccination induces polyfunctional memory CD4 and CD8 T cell responses in patients with solid cancers undergoing immunotherapy or/and chemotherapy.mRNA-1273 疫苗接种可诱导接受免疫治疗和/或化疗的实体瘤患者产生多功能记忆 CD4 和 CD8 T 细胞应答。
Front Immunol. 2024 Aug 27;15:1447555. doi: 10.3389/fimmu.2024.1447555. eCollection 2024.
2
Immune response of COVID-19 vaccines in solid cancer patients: A meta-analysis.COVID-19 疫苗在实体瘤患者中的免疫应答：一项荟萃分析。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2357424. doi: 10.1080/21645515.2024.2357424. Epub 2024 May 24.
3
Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis.

本文引用的文献

1
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety.癌症患者的 COVID-19 疫苗：免疫原性、疗效和安全性。
Nat Rev Clin Oncol. 2022 Jun;19(6):385-401. doi: 10.1038/s41571-022-00610-8. Epub 2022 Mar 11.
2
Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients.新冠疫苗接种者中不同的 SARS-CoV-2 奥密克戎反应性 T 和 B 细胞应答。
Sci Immunol. 2022 Mar 25;7(69):eabo2202. doi: 10.1126/sciimmunol.abo2202.
3
Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer.
成年癌症患者对新冠病毒疫苗全程接种和加强针的体液免疫反应受损，尤其是正在接受积极治疗的血液系统癌症患者：一项系统评价和荟萃分析。
Cancers (Basel). 2023 Apr 12;15(8):2266. doi: 10.3390/cancers15082266.
4
Immune Response following BNT162b2 mRNA COVID-19 Vaccination in Pediatric Cancer Patients.BNT162b2 mRNA新冠疫苗接种后儿科癌症患者的免疫反应
Cancers (Basel). 2023 Apr 29;15(9):2562. doi: 10.3390/cancers15092562.
5
COVID arm that appeared in the contralateral upper extremity after mRNA-1273 booster inoculation.在接种mRNA-1273加强针后出现在对侧上肢的新冠疫苗接种后臂丛神经炎。
Int Cancer Conf J. 2023 Feb 20;12(3):216-219. doi: 10.1007/s13691-023-00598-7. eCollection 2023 Jul.
6
The Scottish COVID Cancer Immunity Prevalence Study: A Longitudinal Study of SARS-CoV-2 Immune Response in Patients Receiving Anti-Cancer Treatment.苏格兰 COVID 癌症免疫患病率研究：接受癌症治疗患者的 SARS-CoV-2 免疫反应纵向研究。
Oncologist. 2023 Mar 17;28(3):e145-e155. doi: 10.1093/oncolo/oyac257.
7
COVID-19 vaccination and liver disease.COVID-19 疫苗接种与肝脏疾病。
World J Gastroenterol. 2022 Dec 28;28(48):6791-6810. doi: 10.3748/wjg.v28.i48.6791.
8
COVID-19 Vaccination Campaign in Cancer Patients and Healthcare Workers-Results from a French Prospective Multicenter Cohort (PAPESCO-19).癌症患者和医护人员的新冠疫苗接种运动——来自法国前瞻性多中心队列研究（PAPESCO-19）的结果
Cancers (Basel). 2022 Nov 11;14(22):5547. doi: 10.3390/cancers14225547.
9
Immunogenicity of an Additional mRNA-1273 SARS-CoV-2 Vaccination in People With HIV With Hyporesponse After Primary Vaccination.mRNA-1273 新冠病毒疫苗加强接种在原发性疫苗接种低反应者中的免疫原性：一项艾滋病毒感染者的研究。
J Infect Dis. 2023 Mar 1;227(5):651-662. doi: 10.1093/infdis/jiac451.
10
Premature aging of the immune system affects the response to SARS-CoV-2 mRNA vaccine in β-thalassemia: role of an additional dose.免疫系统过早衰老影响β地中海贫血患者对SARS-CoV-2 mRNA疫苗的反应：额外一剂疫苗的作用
Blood. 2022 Oct 13;140(15):1735-1738. doi: 10.1182/blood.2022017594.
癌症患者接种第三剂新冠疫苗后的奥密克戎中和抗体
Lancet. 2022 Mar 5;399(10328):905-907. doi: 10.1016/S0140-6736(22)00147-7. Epub 2022 Jan 25.
4
Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer.与实体癌患者相比，血液系统恶性肿瘤患者在第三次接种新冠疫苗后的免疫反应有所降低。
Cancer Cell. 2022 Feb 14;40(2):114-116. doi: 10.1016/j.ccell.2021.12.013. Epub 2021 Dec 29.
5
COVID-19 vaccination and breakthrough infections in patients with cancer.COVID-19 疫苗接种和癌症患者的突破性感染。
Ann Oncol. 2022 Mar;33(3):340-346. doi: 10.1016/j.annonc.2021.12.006. Epub 2021 Dec 24.
6
Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer.BNT162b2 mRNA疫苗加强针在积极治疗的癌症患者中的免疫原性和安全性。
Lancet Oncol. 2022 Feb;23(2):193-195. doi: 10.1016/S1470-2045(21)00715-4. Epub 2021 Dec 23.
7
mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial.mRNA-1273 新冠病毒疫苗在接受化疗、免疫疗法或化疗免疫疗法治疗实体瘤的患者中的应用：一项前瞻性、多中心、非劣效性试验。
Lancet Oncol. 2021 Dec;22(12):1681-1691. doi: 10.1016/S1470-2045(21)00574-X. Epub 2021 Nov 9.
8
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months.辉瑞-BioNTech 新冠疫苗接种 6 个月后免疫体液反应逐渐减弱。
N Engl J Med. 2021 Dec 9;385(24):e84. doi: 10.1056/NEJMoa2114583. Epub 2021 Oct 6.
9
Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.抗肿瘤治疗的癌症患者接种 BNT162b2 冠状病毒病 2019 信使 RNA 疫苗后体液免疫应答降低。
ESMO Open. 2021 Oct;6(5):100274. doi: 10.1016/j.esmoop.2021.100274. Epub 2021 Sep 8.
10
Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study.新冠病毒疫苗接种后成年人新冠相关死亡和住院的风险预测：全国前瞻性队列研究。
BMJ. 2021 Sep 17;374:n2244. doi: 10.1136/bmj.n2244.